Last reviewed · How we verify
Testosterone Product
Testosterone replaces or supplements endogenous testosterone to restore normal androgen levels in hypogonadal patients.
Testosterone replaces or supplements endogenous testosterone to restore normal androgen levels in hypogonadal patients. Used for Hypogonadism in adult males, Testosterone deficiency syndrome.
At a glance
| Generic name | Testosterone Product |
|---|---|
| Sponsor | Bayer |
| Drug class | Androgen replacement therapy |
| Target | Androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Testosterone is a naturally occurring androgen that binds to androgen receptors throughout the body to promote male sexual characteristics, muscle development, bone density, and metabolic function. In hypogonadal men with insufficient endogenous testosterone production, exogenous testosterone replacement restores physiological hormone levels and alleviates symptoms of testosterone deficiency. Bayer markets several testosterone formulations (e.g., Nebido, Aveed) as long-acting depot injections or other delivery systems.
Approved indications
- Hypogonadism in adult males
- Testosterone deficiency syndrome
Common side effects
- Polycythemia
- Acne
- Injection site reactions
- Gynecomastia
- Mood changes
- Prostate-related symptoms
Key clinical trials
- [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer (NA)
- Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening (PHASE4)
- DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment (PHASE2)
- A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer (PHASE2)
- Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer (PHASE1)
- Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations (PHASE2)
- Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (PHASE2)
- Testosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Testosterone Product CI brief — competitive landscape report
- Testosterone Product updates RSS · CI watch RSS
- Bayer portfolio CI